MIST
Milestone Pharmaceuticals Inc. NASDAQ Listed May 9, 2019$1.89
Mkt Cap $162.3M
52w Low $1.00
43.2% of range
52w High $3.06
50d MA $1.70
200d MA $1.89
P/E (TTM)
-2.5x
EV/EBITDA
-2.5x
P/B
3.8x
Debt/Equity
1.4x
ROE
-151.0%
P/FCF
-3.4x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$1.70
200d MA
$1.89
Avg Volume
2.1M
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
1111 Dr. Frederik-Philips Boulevard · Montreal, QC H4M 2X6 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | AMC | -0.18 | -0.16 | +11.1% | 1.36 | +0.0% | -7.4% | -7.9% | +7.8% | -8.0% | -9.6% | — |
| Nov 12, 2025 | AMC | -0.17 | -0.12 | +29.4% | 1.93 | +0.0% | -1.6% | +5.3% | +16.0% | +3.9% | -3.3% | — |
| Aug 12, 2025 | AMC | -0.18 | -0.20 | -11.1% | 1.66 | +3.0% | +4.8% | -3.4% | +1.2% | +0.0% | -1.8% | — |
| May 14, 2025 | AMC | -0.19 | -0.31 | -63.2% | 1.17 | +0.0% | -1.7% | +6.1% | +5.7% | +7.8% | -0.7% | — |
| Mar 13, 2025 | AMC | -0.15 | -0.19 | -26.7% | 2.03 | +5.9% | +6.9% | +11.1% | -1.2% | -16.4% | -2.0% | — |
| Nov 12, 2024 | AMC | -0.16 | -0.14 | +12.5% | 1.87 | -1.6% | -1.6% | -1.6% | -6.1% | +0.0% | +2.4% | — |
| Aug 8, 2024 | AMC | -0.19 | -0.14 | +26.3% | 1.41 | +1.4% | +0.0% | +0.0% | +0.0% | +0.0% | -4.3% | — |
| May 13, 2024 | AMC | -0.26 | -0.21 | +19.2% | 1.70 | +2.4% | +1.2% | +0.6% | +1.2% | -0.6% | +0.6% | — |
| Mar 21, 2024 | AMC | -0.30 | -0.32 | -6.7% | 1.56 | +0.0% | +11.5% | -0.6% | +4.6% | -0.6% | -0.6% | — |
| Nov 13, 2023 | AMC | -0.38 | -0.35 | +7.9% | 2.34 | +1.7% | -4.3% | +1.3% | -1.8% | -1.3% | +3.6% | — |
| Aug 10, 2023 | AMC | -0.39 | -0.37 | +5.1% | 3.30 | -0.9% | -3.9% | -1.3% | +2.2% | -3.8% | +0.6% | — |
| May 11, 2023 | AMC | -0.38 | -0.35 | +7.9% | 4.25 | +0.0% | +3.5% | -4.3% | -6.9% | +2.3% | +2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $2.04 | +1.0% | +1.5% | +4.9% | +1.9% | -6.8% | -3.9% |
| Dec 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.35 | $2.34 | -0.4% | -6.4% | -2.3% | -3.3% | +3.4% | -3.7% |
| Dec 15 | TD Cowen | Upgrade | Hold → Buy | — | $2.41 | $2.91 | +20.7% | -2.5% | -6.4% | -2.3% | -3.3% | +3.4% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.41 | $2.91 | +20.7% | -2.5% | -6.4% | -2.3% | -3.3% | +3.4% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.80 | $0.80 | -0.1% | -5.0% | +5.7% | -6.6% | -7.2% | -2.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $0.76 | -66.0% | -60.9% | -9.1% | -5.0% | +5.7% | -6.6% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.23 | +2.8% | +11.1% | -1.2% | -16.4% | -2.0% | -2.6% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.72 | -1.1% | -6.3% | +1.2% | -0.6% | +20.7% | -4.0% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.05 | $2.04 | -0.5% | -1.5% | -2.0% | +1.0% | +1.0% | -2.5% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.45 | $1.43 | -1.4% | +2.1% | +0.7% | -2.0% | +0.7% | +1.4% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.46 | +4.3% | +2.9% | +2.1% | +2.0% | -2.0% | -1.4% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.37 | +3.8% | +1.5% | +0.7% | -1.5% | +0.0% | +2.3% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.60 | +2.6% | -1.9% | -2.0% | +0.7% | +0.7% | -2.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.73 | +0.0% | +1.2% | -0.6% | +0.6% | -1.7% | +1.7% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.56 | +0.0% | +11.5% | -0.6% | +4.6% | -0.6% | -0.6% |
| Mar 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.55 | $1.49 | -3.9% | +1.9% | -8.2% | +3.4% | +0.7% | +2.0% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.70 | $1.90 | +11.8% | +24.1% | +4.3% | -3.2% | -21.1% | -4.2% |
| Dec 27 | TD Cowen | Maintains | Outperform → Outperform | — | $1.99 | $2.00 | +0.5% | -5.5% | -5.9% | -5.6% | +7.8% | -2.2% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $3.17 | +0.0% | -1.3% | +2.2% | -3.8% | +0.6% | -1.9% |
| Jun 20 | Jefferies | Downgrade | Buy → Hold | — | $3.50 | $3.47 | -0.9% | -1.7% | -3.5% | -2.7% | -2.5% | -3.5% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.10 | $4.16 | +1.5% | +4.9% | +0.0% | -4.7% | -2.9% | +2.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.44 | +0.9% | -4.3% | -6.9% | +2.3% | +2.5% | +4.6% |
| Apr 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.84 | $3.80 | -1.0% | -4.4% | +0.3% | -2.4% | +6.1% | -2.9% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.90 | $3.95 | +1.3% | -1.8% | +2.9% | +1.0% | +2.3% | -2.7% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.74 | $3.75 | +0.3% | -5.3% | -9.6% | +1.9% | +7.7% | +0.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.62 | $4.95 | +7.1% | +0.0% | -5.2% | +3.4% | +0.2% | +0.7% |
| Apr 22 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.15 | $7.50 | +4.9% | -0.7% | -1.3% | -4.6% | -1.3% | -2.1% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.52 | $7.38 | +13.2% | +6.0% | +0.7% | +4.3% | -0.8% | +4.4% |
| Jul 29 | Oppenheimer | Upgrade | Perform → Outperform | — | $8.01 | $8.06 | +0.6% | +9.2% | -1.0% | +0.5% | +8.4% | -0.7% |
| Jul 24 | Jefferies | Upgrade | Hold → Buy | — | $8.91 | $9.00 | +1.0% | -7.1% | +1.8% | -5.0% | +9.2% | -1.0% |
| Mar 25 | Jefferies | Downgrade | Buy → Hold | — | $1.70 | $2.40 | +41.2% | +14.7% | +5.6% | -3.9% | -5.6% | -1.6% |
| Mar 24 | Oppenheimer | Downgrade | Outperform → Perform | — | $14.00 | $3.35 | -76.1% | -87.9% | +14.7% | +5.6% | -3.9% | -5.6% |
| Mar 24 | Piper Sandler | Downgrade | Overweight → Neutral | — | $14.00 | $3.35 | -76.1% | -87.9% | +14.7% | +5.6% | -3.9% | -5.6% |
| Jun 3 | Piper Jaffray | Maintains | Overweight → Overweight | — | $20.70 | $20.68 | -0.1% | -3.3% | +1.9% | +0.7% | -3.4% | +0.7% |
| Jun 3 | Jefferies | Maintains | Buy → Buy | — | $20.70 | $20.68 | -0.1% | -3.3% | +1.9% | +0.7% | -3.4% | +0.7% |
No insider trades available.
Data updated apr 26, 2026 12:22pm
· Source: massive.com